US FDA accepts Sandoz Biologics License Application
Sandoz Biologics License Application for proposed biosimilar denosumab accepted by US FDA Sandoz, a global leader in off-patent (generic and biosimilar) medicines, has announced that the US Food and Drug Administration (US FDA) has accepted its Biologics License Application (BLA) for proposed biosimilar denosumab. The application includes all indications covered by the reference medicines Prolia® (denosumab) […]
US FDA accepts Sandoz Biologics License Application Read More »